Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Invest New Drugs. 2017 Oct 9;36(3):442–450. doi: 10.1007/s10637-017-0519-z

Table 1.

Dose Escalation Schedule (standard 3+3 design) with Dose Limiting Toxicities

Dose Level Gemcitabine
(mg/m2)
Erlotinib
(mg QD)
Dasatinib
(mg QD)
Cycle 1 (28-days) Toxicity
Level -1 800 100 50 6 patients; 1/6 with DLTa
Level 0 (starting) 800 100 70 6 patients; 1/6 with DLTb
Level 1 800 100 100 7 patients (6 evaluable); 1/6 with DLTc
Level 2 1000 100 100 Not Evaluated
Level 3 1000 100 140 Not Evaluated
a

Grade 3 dyspnea;

b

Grade 3 nausea and vomiting;

c

Grade 3 elevated AST

QD: once daily; AST: aspartate aminotransferase